Taking the next step in your DLBCL journey

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). More than 18,000 people are diagnosed with DLBCL in the United States each year.

DLBCL is a fast-growing NHL. It affects B-lymphocytes, also known as B cells, a type of white blood cell that helps your body fight infections. As they develop, cancerous B cells become larger than normal and multiply uncontrollably.

From having lived with DLBCL before, you know the ups and downs that can come with this cancer. Your healthcare team has suggested treatment with MONJUVI because your DLBCL has relapsed (returned) or become refractory (stopped responding) after at least one previous treatment.

Many people with DLBCL need another option after their first treatment stops working. Up to 50% of patients who receive standard first-line treatment relapse after achieving a complete response or are refractory to treatment.

Learn about how MONJUVI was studied and how it may help.